OptimizeRx (OPRX) Fundamentals 2026 — P/E 17.9x, Revenue Analysis | SniperIQ
OptimizeRx (OPRX) is a US-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is OptimizeRx's market cap?
OptimizeRx (OPRX) has a market capitalization of approximately
What is OptimizeRx's P/E ratio?
OptimizeRx's trailing twelve-month P/E ratio is 17.9x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is OptimizeRx?
OptimizeRx runs a net profit margin of 6.4%, a gross margin of 69.0%, and an operating margin of 13.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does OptimizeRx generate?
OptimizeRx reported revenue of
Does OptimizeRx pay a dividend?
OptimizeRx does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is OptimizeRx financially healthy?
OptimizeRx carries a debt-to-equity ratio of 0.18x and a current ratio of 5.37x, with a market beta of 1.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is OptimizeRx a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For OptimizeRx (OPRX) the key facts are: market cap
Track OptimizeRx's full fundamentals live
Get OptimizeRx's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.